Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys

被引:98
作者
Schröder, C
Azimzadeh, AM
Wu, GS
Price, JO
Atkinson, JB
Pierson, RN [1 ]
机构
[1] Vanderbilt Univ, Dept Cardiothorac Surg, Nashville, TN 37240 USA
[2] VAMC, TN Valley Healthcare Syst, Nashville, TN 37212 USA
[3] Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA
[4] Univ Maryland, Div Cardiac Surg, Baltimore, MD 21201 USA
基金
美国国家卫生研究院;
关键词
anti-CD20; therapy; B-cell depletion; non-human primate; plasma cell; allo-antibodies;
D O I
10.1016/S0966-3274(03)00059-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Macaque species offer a valuable model for translational allo-transplantation and tolerance studies. Cardiac allograft vasculopathy in Macaca fascicularis is associated with elaboration of anti-donor antibodies. Since T-independent pathways of B cell activation have been described, and anti-B cell strategies have proven to be a fruitful tolerogenic adjunct in rodent and xenogenic models, here we investigate whether an anti-CD20 antibody (rituximab) would be useful to deplete B-cells in a pre-clinical allo-transplantation setting in macaques. Methods: Three cynomolgus macaques which had previously rejected a cardiac allograft and one with concurrent subacute vascular rejection were treated weekly with rituximab 20 mg/kg IV for 4 and 2 weeks, respectively. B-cell levels (CD19+ cells) were measured by flow cytometry in peripheral blood, spleen, lymph node and bone marrow cells at various intervals after initiation of treatment. B-cells and plasma cells were also analyzed by immunohistochemistry at necropsy in spleen, lymph node, tonsil and thymus tissue sections. Anti-donor antibody titers were measured by flow cytometry. Results: B-cells expressing CD19 were not detectable in the peripheral blood in any animal within 24 It after initial treatment, or over the ensuing month. At necropsy, the germinal centers in spleen and lymph node were completely depleted of CD20+ B-cells in 2 animals, leaving a hypocellular trabecular pattern around preserved plasma cell follicles. Substantial but incomplete depletion of B-cells was demonstrated in the other 2 animals, in each instance immunohistochemical findings in spleen and lymph node exhibiting higher sensitivity for residual B-cells compared to FACS. Anti-donor antibody titers exhibited kinetics similar to untreated animals over this short follow-up. Comment: Treatment with anti-CD20 very efficiently depletes peripheral and tissue B-cells but not plasma cells in this macaque species. Biopsy of lymph node is necessary and may be sufficient to assess B-cell clearance in secondary lymphoid organs in this model. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:19 / 28
页数:10
相关论文
共 25 条
[1]   Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression [J].
Adams, AB ;
Durham, MM ;
Kean, L ;
Shirasugi, N ;
Ha, JW ;
Williams, MA ;
Rees, PA ;
Cheung, MC ;
Mittelstaedt, S ;
Bingaman, AW ;
Archer, DR ;
Pearson, TC ;
Waller, EK ;
Larsen, CP .
JOURNAL OF IMMUNOLOGY, 2001, 167 (02) :1103-1111
[2]   Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons:: depletion of CD20-and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody [J].
Alwayn, IPJ ;
Xu, YX ;
Basker, M ;
Wu, C ;
Buhler, L ;
Lambrigts, D ;
Treter, S ;
Harper, D ;
Kitamura, H ;
Vitetta, ES ;
Abraham, S ;
Awwad, M ;
White-Scharf, ME ;
Sachs, DH ;
Thall, A ;
Cooper, DKC .
XENOTRANSPLANTATION, 2001, 8 (03) :157-171
[3]   Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].
Cartron, G ;
Dacheux, L ;
Salles, G ;
Solal-Celigny, P ;
Bardos, P ;
Colombat, P ;
Watier, H .
BLOOD, 2002, 99 (03) :754-758
[4]   Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma [J].
Cohen, Y ;
Polliack, A ;
Zelig, O ;
Goldfarb, A .
LEUKEMIA & LYMPHOMA, 2001, 42 (06) :1405-1408
[5]   B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders [J].
Edwards, JCW ;
Leandro, MJ ;
Cambridge, G .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2002, 30 :824-828
[6]   Resting B lymphocytes as APC for naive T lymphocytes: Dependence on CD40 ligand/CD40 [J].
Evans, DE ;
Munks, MW ;
Purkerson, JM ;
Parker, DC .
JOURNAL OF IMMUNOLOGY, 2000, 164 (02) :688-697
[7]  
Grammer AC, 1999, J IMMUNOL, V163, P4150
[8]   Clearance of erythrocyte allo-antibodies using Rituximab [J].
Gryn, J ;
Zeigler, ZR ;
Shadduck, RK ;
Thomas, C .
BONE MARROW TRANSPLANTATION, 2002, 29 (07) :631-632
[9]   Complement activation in circulation and central nervous system after Rituximab (Anti-CD20) treatment of B-Cell lymphoma [J].
Harjunpää, A ;
Wiklund, T ;
Collan, J ;
Janes, R ;
Rosenberg, J ;
Lee, D ;
Grillo-López, A ;
Meri, S .
LEUKEMIA & LYMPHOMA, 2001, 42 (04) :731-738
[10]   B-cell development in the thymus is limited by inhibitory signals from the thymic microenvironment [J].
Hashimoto, Y ;
Montecino-Rodriguez, E ;
Leathers, H ;
Stephan, RP ;
Dorshkind, K .
BLOOD, 2002, 100 (10) :3504-3511